MNKD (MannKind Corporation) Stock Financials & Earnings | Market Cap Arena

MNKD (MannKind Corporation) Stock Financials & Earnings | Market Cap Arena

MNKDMannKind Corporation

Mkt Cap$813M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$349M

Net Income (TTM)$6M

EPS (TTM)$0.02

Free Cash Flow (TTM)$14M

Gross Margin76.4%

Op. Margin11.1%

Net Margin1.7%

FCF Margin3.9%

P/S Ratio (TTM)2.3x

P/E Ratio (TTM)138.7x

YoY Rev Growth+22.2%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$41M	$24M	-$6M
Q2 23	$49M	$34M	$2M
Q3 23	$51M	$37M	$5M
Q4 23	$58M	$40M	$8M
Q1 24	$66M	$48M	$17M
Q2 24	$72M	$52M	$17M
Q3 24	$70M	$52M	$13M
Q4 24	$77M	$57M	$26M
Q1 25	$78M	$61M	$22M
Q2 25	$77M	$56M	$5M
Q3 25	$82M	$62M	$19M
Q4 25	$112M	$88M	-$8M

Valuation

Quarter	P/S	P/E
Q1 23	6.3x	—
Q2 23	5.1x	—
Q3 23	4.6x	—
Q4 23	4.1x	—
Q1 24	3.6x	95.8x
Q2 24	3.3x	69.3x
Q3 24	3.0x	37.7x
Q4 24	2.8x	29.5x
Q1 25	2.7x	27.0x
Q2 25	2.7x	24.8x
Q3 25	2.6x	27.8x
Q4 25	2.3x	138.7x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$1M	-$7M
Q2 23	$3M	-$14M
Q3 23	$9M	-$3M
Q4 23	$22M	$16M
Q1 24	$7M	$4M
Q2 24	$4M	$861K
Q3 24	$9M	$8M
Q4 24	$23M	$20M
Q1 25	-$6M	-$7M
Q2 25	$9M	$8M
Q3 25	$23M	$22M
Q4 25	-$8M	-$10M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$8M
Q2 23	$17M
Q3 23	$11M
Q4 23	$6M
Q1 24	$2M
Q2 24	$3M
Q3 24	$1M
Q4 24	$3M
Q1 25	$330K
Q2 25	$1M
Q3 25	$1M
Q4 25	$2M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+238.8%	+40.2%
Q2 23	+157.3%	+19.2%
Q3 23	+56.1%	+8.8%
Q4 23	+62.2%	+3.6%
Q1 24	+63.1%	+6.3%
Q2 24	+48.9%	+19.0%
Q3 24	+36.7%	+24.2%
Q4 24	+31.3%	-0.7%
Q1 25	+18.2%	+13.2%
Q2 25	+5.7%	+27.7%
Q3 25	+17.2%	+10.5%
Q4 25	+45.8%	+137.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$4M	9.0%
Q2 23	$6M	11.5%
Q3 23	$5M	9.0%
Q4 23	$4M	6.5%
Q1 24	$4M	5.9%
Q2 24	$6M	8.9%
Q3 24	$5M	7.5%
Q4 24	$6M	7.6%
Q1 25	$5M	6.9%
Q2 25	$8M	9.8%
Q3 25	$0	0.0%
Q4 25	$7M	6.2%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$6M	$11M	$13M	—
Q2 23	$6M	$12M	$14M	—
Q3 23	$10M	$11M	$13M	—
Q4 23	$9M	$10M	$11M	—
Q1 24	$10M	$11M	$12M	—
Q2 24	$12M	$13M	$11M	—
Q3 24	$13M	$11M	$13M	—
Q4 24	$11M	—	—	$24M
Q1 25	$11M	—	—	$25M
Q2 25	$14M	—	—	$32M
Q3 25	$14M	$14M	$15M	—
Q4 25	$28M	—	—	$58M

Revenue Segments

Quarter	License And Service	Product	Royalty	Product Revenue	Service
Q2 24	$26M	$21M	$26M	—	—
Q3 24	$23M	$20M	$27M	—	—
Q1 25	$29M	$19M	$30M	—	—
Q2 25	—	—	$31M	$45M	$621K
Q3 25	—	—	$33M	$48M	$537K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$86M	$80M	$166M
Q2 23	$86M	$58M	$144M
Q3 23	$83M	$58M	$141M
Q4 23	$238M	$57M	$295M
Q1 24	$193M	$107M	$301M
Q2 24	$97M	$151M	$248M
Q3 24	$62M	$189M	$252M
Q4 24	$46M	$151M	$197M
Q1 25	$47M	$134M	$182M
Q2 25	$57M	$122M	$179M
Q3 25	$127M	$133M	$260M
Q4 25	$75M	$96M	$171M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	264M	+0.2%
Q2 23	266M	+0.6%
Q3 23	269M	+1.2%
Q4 23	324M	+20.5%
Q1 24	325M	+0.3%
Q2 24	273M	-15.9%
Q3 24	285M	+4.3%
Q4 24	291M	+2.1%
Q1 25	321M	+10.4%
Q2 25	311M	-2.9%
Q3 25	312M	+0.0%
Q4 25	314M	+0.8%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$0	287
FY 15	$0	192
FY 16	$1M	153
FY 17	$47K	250
FY 18	$124K	225
FY 19	$271K	233
FY 20	$270K	241
FY 21	$216K	349
FY 22	$253K	395
FY 23	$481K	414
FY 24	$701K	407
FY 25	$589K	592